Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Botulinum toxin may help treat male pattern baldness.

In this retrospective analysis, patients with trichodynia who were unresponsive to standard treatments showed significant symptom improvement after receiving intradermal botulinum toxin type A, with nearly all patients benefiting, particularly those with scarring alopecia.

In this study, botulinum toxin type A injections reduced the severity of treatment-resistant scalp psoriasis in more patients compared to placebo over a 12-week period.

This study found that intrauterine administration of botulinum toxin A improved endometrial environment and receptivity in a murine model of thin endometrium through mechanisms involving IGFBP3 and osteopontin.

This review reports that while botulinum toxin shows potential mechanisms for treating androgenetic alopecia, recent high-quality trials found no significant hair density improvement compared to placebo, indicating it can't yet replace traditional treatments.

Botulinum A toxin injections reduced pain and promoted hair regrowth in a woman with a rare form of alopecia areata.

This registered trial will investigate whether preoperative botulinum toxin can improve hair transplantation outcomes by enhancing blood flow and reducing ischemia in the scalp.

This study observed that combining botulinum toxin type A with Minoxidil significantly promoted hair growth, improved quality of life, and enhanced patient satisfaction in male androgenetic alopecia patients at 4 and 6 months, with no adverse effects compared to using Minoxidil alone.

This systematic review found inconclusive evidence on the effectiveness of botulinum toxin for treating alopecia and highlighted the need for further prospective randomized controlled trials.

The study found that botulinum toxin-A significantly increased the diameter of the supratrochlear artery in a small patient group, suggesting potential vasodilatory benefits for treating ischemic conditions.

In this study, BTXA injections did not effectively treat recalcitrant alopecia areata or improve hair regrowth in most patients, suggesting its limitations as an alternative therapy.

This article discusses the authors’ response to comments on their study about intradermal botulinum toxin's effect on androgenetic alopecia, reporting no new findings.

This document reviews various types of microbes, their roles in fermentation and diseases, and strategies for protection against microbial infections, but presents no new research findings.

In this study, combining Botulinum toxin type A with Platelet-rich plasma was found to enhance hair follicle growth and reconstruction, potentially through inflammation reduction and activation of the Wnt/β-catenin pathway via STMN1 protein modulation.

This study found that a single session of botulinum toxin, whether administered subcutaneously or combined intramuscularly and subcutaneously, did not significantly improve hair density or hair quality in men with androgenetic alopecia after six months.

This study found that botulinum toxin type A significantly reduced skin flap necrosis in rats exposed to cigarette smoke, suggesting it may help improve flap viability in smokers.

This case study reports an epidermoid cyst diagnosis in a woman who developed swelling in the left parotid gland following botulinum toxin injection in the left masseter muscles.

In this study of patients with androgenetic alopecia, botulinum toxin type A was found to significantly increase hair counts and improve hair density and coverage, with enhanced results observed when combined with oral finasteride, revealing a safe and effective treatment approach without adverse effects.

This study suggests that while subcutaneous Botulinum Toxin Type A may offer short-term symptom improvement for female pattern hair loss, its effectiveness does not extend beyond three months.

In this randomized controlled trial, both Botulinum Toxin-A and Triamcinolone Acetonide showed substantial effectiveness in treating patchy Alopecia Areata, but Botulinum Toxin-A avoided complications while Triamcinolone led to skin atrophy in 16.7% of patients.

This article discusses various dermatological topics from different journals but does not present any new clinical findings.

This systematic review of five studies found that intradermal and intramuscular botulinum toxin injections showed promising hair growth outcomes for men with androgenic alopecia, but emphasizes caution due to a lack of control groups and small sample sizes.

The study did not find evidence to support using botulinum toxin as a treatment for androgenetic alopecia.

This review discusses the potential mechanisms by which intradermal botulinum toxin may affect androgenetic alopecia but notes that high-evidence clinical trials have yet to show conclusive results.

This article reviews various cosmetic procedures like botulinum A exotoxin and chemical peels for aesthetic enhancement but reports no new clinical findings, emphasizing existing methods.

In this case study, repetitive botulinum type A toxin injections led to almost complete resolution of severe chronic pain in a patient with Parry-Romberg syndrome.

This review discusses the most popular non-surgical cosmetic procedures pursued by men and highlights the importance of sex-specific considerations in treating male cosmetic patients; it reports no new clinical results.

Botulinum toxin may help hair loss by increasing blood flow and reducing harmful factors.

In this case report, off-label onabotulinumtoxin-A was successfully used to treat trichodynia, a painful scalp sensation associated with hair loss, in a patient unresponsive to conventional therapies.

Botulinum toxin-A may increase hair growth and reduce hair loss in men with baldness, and injecting near blood vessels can improve pain relief and last longer.